ABEO Stock Discussion
Abeona Therapeutics Inc. Description
Abeona Therapeutics, Inc., formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for severe and rare diseases. The Company's lead program includes adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB). Its product pipeline includes ABO-101 (sc AAV9 NAGLU), which is used for the treatment of MPS III B; ABO-102 (sc AAV9 SGSH), which is used for the treatment of MPS III A; ABO-201 (sc AAV9 CLN3), which is used for the treatment of Juvenile Batten Disease (JBD); ABO-301 (AAV LK19 FANCC), which is used for the treatment of Fanconi Anemia (FA), and clustered, regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) gene editing, which is used for treatment of other rare blood diseases. The Company offers two platforms: Salt Diafiltration (SDF) Process and Polymer Hydrogel Technology (PHT).
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Biology Emerging Technologies Molecular Biology Rare Diseases Gene Therapy Genetics Genetic Engineering Anemia CRISPR Genome Editing Adeno Associated Virus Cas9 Severe And Rare Diseases Blood Diseases Fanconi Anemia
Recent Comments
- Cos3 on Adding float as advanced filter criteria?
- FriendlyOyster657 on BOOT
- TraderMike on Filtering by News?
- Dr_Duru on Filtering by News?
- TraderMike on Filtering by News?
From the Blog
Featured Articles